KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs to…
Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Incyte’s ruxolitinib (Jakafi, approved November 2011) and Bristol Myers…
Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key pancreatic cancer patient populations covering 171 countries and more…